Last updated on July 2018

The Safety Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors


Brief description of study

The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Clinical Study Identifier: NCT02660034

Contact Investigators or Research Sites near you

Start Over

Ginny Paton, MD.

Fox Chase Cancer Center
Philadelphia, PA United States
1.35miles
  Connect »